M. Soleda

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

E. Felip, S. Cedrés, A. Navarro, 2022, Journal for ImmunoTherapy of Cancer.

Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC

E. Felip, S. Cedrés, A. Navarro, 2023, Molecular oncology.